Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15956326 | 0.89 | HPGD (0.45) | FFAR1FFAR4 | |
| SCHEMBL3152947 | 0.84 | CYP4F2 (0.51) | FFAR1 | |
| SCHEMBL18642578 | 0.83 | FFAR1 (0.66) | FFAR1FFAR4 | |
| SCHEMBL1551350 | 0.82 | FFAR1 (0.68) | ADRB2ADRB1FFAR1FFAR4CYP11B1 | |
| SCHEMBL1550669 | 0.81 | FFAR1 (0.68) | FFAR1FFAR4 | |
| SCHEMBL21778356 | 0.81 | ADRB2 (0.49) | ADRB2ADRB1FFAR1FFAR4 | |
| SCHEMBL1550285 | 0.81 | FFAR1 (0.69) | ADRB2ADRB1FFAR1FFAR4 | |
| SCHEMBL15820059 | 0.80 | FFAR1 (0.48) | ADRB2ADRB1FFAR1FFAR4CYP11B1 | |
| SCHEMBL3686971 | 0.80 | ADRB2 (0.48) | ADRB2ADRB1FFAR1FFAR4 | |
| SCHEMBL22922181 | 0.80 | CYP4F2 (0.59) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026018-B | Diphenylacetylene compound | 国立大学法人大阪大学 | 2021-01-15 | — | — | CN | disclosed |
| US-10577396-B2 | Tolan compound | OSAKA UNIVERSITY (JP) | 2020-03-03 | — | — | US | disclosed |
| US-10577396-B2 | Tolan compound | OSAKA UNIVERSITY (JP) | 2020-03-03 | — | — | US | disclosed |
| US-20180258141-A1 | TOLAN COMPOUND | OSAKA UNIVERSITY (JP) | 2018-09-13 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2598486-B1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| EP-2598486-B1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| WO-2017047807-A1 | TOLAN COMPOUND | 国立大学法人大阪大学 | 2017-03-23 | — | — | WO | disclosed |
| US-8586607-B2 | Compounds for the treatment of metabolic diseases | SYDDANSK UNIVERSITET (DK) | 2013-11-19 | — | — | US | disclosed |
| EP-2598486-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | Novartis AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| EP-2313360-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | UNIV SYDDANSK (DK) | 2012-09-05 | — | — | EP | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
| EP-2313360-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | Syddansk Universitet (DK) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010012650-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET (DK) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577396-B2 | Tolan compound | TAP1, GRN, TSG101 | ADRB2 3106/4885ADRB1 2160/4885FFAR1 3436/4885 |
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | ADRB2 214/4885ADRB1 54/4885FFAR1 6/4885 |
| US-20180258141-A1 | TOLAN COMPOUND | TAP1, GRN, TSG101 | ADRB2 3106/4885ADRB1 2160/4885FFAR1 3436/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | ADRB2 3043/4885ADRB1 1874/4885FFAR1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.